Atsuko Kamijo-Ikemori

List of Publications by Year
in descending order

Version: 2024-02-01

39 papers	1,027 citations	516710 16 h-index	434195 31 g-index
39 all docs	39 docs citations	39 times ranked	1001 citing authors

#	Article	IF	Citations
1	Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats. Molecular and Cellular Endocrinology, 2022, 539, 111472.	3.2	6
2	Endurance Exercise Training-Attenuated Diabetic Kidney Disease with Muscle Weakness in Spontaneously Diabetic Torii Fatty Rats. Kidney and Blood Pressure Research, 2022, 47, 203-218.	2.0	4
3	Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats. BMC Ophthalmology, 2022, 22, 206.	1.4	4
4	Angiotensin II type 1a receptor loss ameliorates chronic tubulointerstitial damage after renal ischemia reperfusion. Scientific Reports, 2021, 11, 982.	3.3	4
5	Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats. Clinical and Experimental Nephrology, 2021, 25, 365-375.	1.6	16
6	Clinical Utility of Urinary Biomarkers for Prediction of Acute Kidney Injury and Chronic Renal Dysfunction After Open Abdominal Aortic Aneurysm Repair. International Journal of Nephrology and Renovascular Disease, 2021, Volume 14, 371-384.	1.8	3
7	Quantitative and qualitative analyses of urinary L-FABP for predicting acute kidney injury after emergency laparotomy. Journal of Anesthesia, 2021, , 1.	1.7	3
8	Incremental short maximal exercise increases urinary liverâ€type fatty acidâ€binding protein in adults without CKD. Scandinavian Journal of Medicine and Science in Sports, 2020, 30, 709-715.	2.9	5
9	Relationship between Urinary Liver-Type Fatty Acid-Binding Protein (L-FABP) and Sarcopenia in Spontaneously Diabetic Torii Fatty Rats. Journal of Diabetes Research, 2020, 2020, 1-14.	2.3	8
10	Renoprotective effects of voluntary running exercise training on aldosterone-induced renal injury in human L-FABP chromosomal transgenic mice. Hypertension Research, 2019, 42, 1518-1527.	2.7	6
11	The Possibility of Urinary Liver-Type Fatty Acid-Binding Protein as a Biomarker of Renal Hypoxia in Spontaneously Diabetic Torii Fatty Rats. Kidney and Blood Pressure Research, 2019, 44, 1476-1492.	2.0	8
12	Utility of urinary tubular markers for monitoring chronic tubulointerstitial injury after ischemiaâ€“reperfusion. Nephrology, 2018, 23, 308-316.	1.6	11
13	Urinary Level of Liver-Type Fatty Acid Binding Protein Reflects the Degree of Tubulointerstitial Damage in Polycystic Kidney Disease. Kidney and Blood Pressure Research, 2018, 43, 1716-1729.	2.0	11
14	Role of bardoxolone methyl, a nuclear factor erythroid 2-related factor 2 activator, in aldosterone- and salt-induced renal injury. Hypertension Research, 2018, 41, 8-17.	2.7	21
15	Increase in urinary markers during the acute phase reflects the degree of chronic tubulointerstitial injury after ischemia-reperfusion renal injury. Biomarkers, 2017, 22, 5-13.	1.9	9
16	Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetateâ€“salt hypertension. FASEB Journal, 2017, 31, 72-84.	0.5	4
17	Association between muscular strength and intrarenal vascular resistance in middle-aged and older individuals. Experimental Gerontology, 2017, 91, 72-78.	2.8	5
18	Relationship between exercise capacity and urinary liver-type fatty acid-binding protein in middle-aged and older individuals. Clinical and Experimental Nephrology, 2017, 21, 810-817.	1.6	13

#	Article	IF	Citations
19	Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1a receptor expression. European Journal of Pharmacology, 2017, 815, 88-97.	3.5	11
20	Urinary excretion of liver-type fatty acid-binding protein reflects the severity of sepsis. Renal Replacement Therapy, 2017, 3, .	0.7	9
21	Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury. American Journal of Physiology - Renal Physiology, 2016, 310, F1366-F1376.	2.7	22
22	Clinical usefulness of urinary liver-type fatty-acid-binding protein as a perioperative marker of acute kidney injury in patients undergoing endovascular or open-abdominal aortic aneurysm repair. Journal of Anesthesia, 2016, 30, 89-99.	1.7	25
23	Clinical utility of urinary liver-type fatty acid binding protein measured by latex-enhanced turbidimetric immunoassay in chronic kidney disease. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1645-1654.	2.3	5
24	Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD. Clinical and Experimental Nephrology, 2016, 20, 195-203.	1.6	37
25	Distinct Roles of Urinary Liver-Type Fatty Acid-Binding Protein in Non-Diabetic Patients with Anemia. PLoS ONE, 2015, 10, e0126990.	2.5	13
26	Human liver-type fatty acidâ€“binding protein protects against tubulointerstitial injury in aldosterone-induced renal injury. American Journal of Physiology - Renal Physiology, 2015, 308, F114-F121.	2.7	14
27	Renoprotective effect of renal liver-type fatty acid binding protein and angiotensin II type 1a receptor loss in renal injury caused by RAS activation. American Journal of Physiology - Renal Physiology, 2014, 306, F655-F663.	2.7	12
28	Novel Urinary Biomarkers in Early Diabetic Kidney Disease. Current Diabetes Reports, 2014, 14, 513.	4.2	28
29	Urinary liver type fatty acid binding protein in diabetic nephropathy. Clinica Chimica Acta, 2013, 424, 104-108.	1.1	60
30	Renal Liver-Type Fatty Acid Binding Protein Attenuates Angiotensin IIâ€“Induced Renal Injury. Hypertension, 2012, 60, 973-980.	2.7	27
31	Usefulness of Urinary Biomarkers in Early Detection of Acute Kidney Injury After Cardiac Surgery in Adults. Circulation Journal, 2012, 76, 213-220.	1.6	88
32	Roles of human liver type fatty acid binding protein in kidney disease clarified using hLâ€FABP chromosomal transgenic mice. Nephrology, 2011, 16, 539-544.	1.6	38
33	Clinical significance of tubular and podocyte biomarkers in acute kidney injury. Clinical and Experimental Nephrology, 2011, 15, 220-225.	1.6	43
34	Clinical Significance of Urinary Liver-Type Fatty Acidâ€“Binding Protein in Diabetic Nephropathy of Type 2 Diabetic Patients. Diabetes Care, 2011, 34, 691-696.	8.6	126
35	Urinary Fatty Acids and Liver-Type Fatty Acid Binding Protein in Diabetic Nephropathy. Nephron Clinical Practice, 2009, 112, c148-c156.	2.3	52
36	Amelioration of diabetic tubulointerstitial damage in liver-type fattyÂacid-binding protein transgenic mice. Nephrology Dialysis Transplantation, 2009, 24, 788-800.	0.7	38

#	Article	IF	Citations
37	Urinary Excretion of Liver Type Fatty Acid Binding Protein Accurately Reflects the Degree of Tubulointerstitial Damage. American Journal of Pathology, 2009, 174, 2096-2106.	3.8	87
38	Liver-Type Fatty Acid-Binding Protein Attenuates Renal Injury Induced by Unilateral Ureteral Obstruction. American Journal of Pathology, 2006, 169, 1107-1117.	3.8	72
39	Urinary fatty acid binding protein in renal disease. Clinica Chimica Acta, 2006, 374, 1-7.	1.1	79